A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)

NCT00539968 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer
Breast Cancer
Ovarian Cancer
Lung Cancer
Gastric Cancer

Interventions

DRUG: Docetaxel plus lonafarnib

Sponsor

Merck Sharp & Dohme LLC